Eli Lilly and Company· @EliLillyandCo · X·· 1 天前AI 评分22
AI 导读
面向HCP的新信息：在#EASD2026年会上公布的一项新的间接治疗比较，将我们的双GIP/GLP-1减重药物的最高剂量与另一种减重药物的最高剂量进行了比较。阅读更多：https://go.lilly.com/n8w0ye
正文
New information for HCPs: A new indirect treatment comparison presented at the #EASD2026 annual meeting compared the highest dose of our dual GIP/GLP-1 obesity medicine with the highest dose of another obesity medicine. Read more: https://go.lilly.com/n8w0ye
来源：Eli Lilly and Company · x.com